Clinical Supply Agreement Sample Contracts

Kiniksa Pharmaceuticals, Ltd. – Clinical Supply Agreement (April 27th, 2018)

THIS CLINICAL SUPPLY AGREEMENT (Agreement) effective as of September 27, 2017 (Effective Date), is by and between Regeneron Pharmaceuticals, Inc. (Regeneron), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (KINIKSA). Regeneron and KINIKSA are sometimes hereinafter referred to as a Party and collectively as the Parties.

Third Amendment to Drug Clinical Supply Agreement (April 26th, 2018)

THIS THIRD AMENDMENT (this "Amendment"), effective as of the last date of signature hereof (the "Amendment Effective Date"), is made to that certain Drug Clinical Supply Agreement, dated as of February 9, 2014, by and between Bellerophon Pulse Technologies LLC ("Pulse Technologies") and Mallinckrodt Manufacturing LLC, assignee of INO Therapeutics LLC ("Mallinckrodt"), as amended by Section 6 of that certain Second Amendment to Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement, dated as of July 27, 2015, and as amended further by that certain Second Amendment to Drug Clinical Supply Agreement and Third Amendment to Exclusive Cross-License, Technology Transfer and Regulatory Matters Agreement, dated as of November 16, 2015 (collectively, the "Agreement"). Capitalized terms used herein not otherwise defined shall have the meanings ascribed to them in the Agreement.

Amendment No. 32 to the Process Development and Clinical Supply Agreement (February 27th, 2018)

This Amendment No. 32 (the "32nd Amendment"), effective as of September 1, 2017 (the "32nd Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendm

Pursuant to Process Development and Clinical Supply Agreement of November 29, 2007, as Amended (February 27th, 2018)

This Work Order No. 1 is effective as of September 1, 2017 (the "Work Order No. 1 Effective Date"), subject to the terms and conditions of the Process Development and Clinical Supply Agreement, as amended (the "Agreement"), effective as of November 29, 2007 by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"). FibroGen and BI shall be referred to individually herein as a "Party", and collectively as the "Parties".

Kiniksa Pharmaceuticals, Ltd. – Clinical Supply Agreement (February 27th, 2018)

THIS CLINICAL SUPPLY AGREEMENT (Agreement) effective as of September 27, 2017 (Effective Date), is by and between Regeneron Pharmaceuticals, Inc. (Regeneron), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (KINIKSA). Regeneron and KINIKSA are sometimes hereinafter referred to as a Party and collectively as the Parties.

Amendment No. 31 to the Process Development and Clinical Supply Agreement (May 9th, 2017)

This Amendment No. 31 (the "31st Amendment"), effective as of the date of the last signature (the "31st Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, A

Amendment No. 28 to the Process Development and Clinical Supply Agreement (November 8th, 2016)

This Amendment No. 28 (the "28th Amendment"), effective as of the date of the last signature (the "28th Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, A

Amendment No. 27 to the Process Development and Clinical Supply Agreement (November 8th, 2016)

This Amendment No. 27 (the "27th Amendment"), effective as of the date of the last signature (the "26th Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, A

Amendment No. 24 to the Process Development and Clinical Supply Agreement (August 8th, 2016)

This Amendment No. 24 (the "24th Amendment"), retroactively effective as of September 15, 2015 (the "24th Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012,

Amendment No. 22 to the Process Development and Clinical Supply Agreement (August 8th, 2016)

This Amendment No. 22 (the "Twenty-second Amendment"), effective as of April 14, 2016 (the "Twenty-second Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 201

Amendment No. 25 to the Process Development and Clinical Supply Agreement (August 8th, 2016)

This Amendment No. 25 (the "25th Amendment"), retroactively effective as of October 15, 2015 (the "25th Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (""), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment

Amendment No. 26 to the Process Development and Clinical Supply Agreement (August 8th, 2016)

This Amendment No. 26 (the "26th Amendment"), effective as of the date of the last signature (the "26th Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, A

Second Amendment to Drug Clinical Supply Agreement and Third Amendment to Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement (January 12th, 2016)

THIS SECOND AMENDMENT TO DRUG CLINICAL SUPPLY AGREEMENT AND THIRD AMENDMENT TO EXCLUSIVE CROSS-LICENSE, TECHNOLOGY TRANSFER, AND REGULATORY MATTERS AGREEMENT (this "Amendment") is entered into the later of the dates in the signature block below (the "Amendment Effective Date") by and between INO Therapeutics LLC, a Delaware limited liability company having a place of business at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 ("Ikaria"), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at 184 Liberty Corner Road, Suite 302, Warren, NJ 07059 ("Pulse Technologies").

Amendment No. 23 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

This AMENDMENT No. 23 (the "Twenty-third Amendment"), effective as of September 01, 2015 (the "Twenty-Third Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer lngelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012

Amendment No. 16 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

THIS AMENDMENT No. 16 (the "Sixteenth Amendment"), effective as of December 08, 2014 (the "Sixteenth Amendment Effective Date") by and between BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH, Binger Str. 173, 55216 Ingelheim, German y ("BI") and FIBROGEN, INC., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement originally entered into by and between BOEHRINGER INGELHEIM PHARMA GMBH & Co. KG , Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1 , effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No . 4, effective as of January 24, 2011 , Amendment No. 5, effective as of Apri1 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January I , 2012, Amendment No. 8, effective a

Amendment No.19 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

THIS AMENDMENT No. 19 (the "Nineteenth Amendment"), effective as of March 01, 2015 (the "Nineteenth Amendment Effective Date") by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 05, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 20

Amendment No.17 Tothe Process Development and Clinical Supply Agreement (November 12th, 2015)

THIS AMENDMENT No. 17 (the "Seventeenth Amendment"), effective as of December 08, 2014 (the "Seventeenth Amendment Effective Date") by and between BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH, Binger Str. 173, 55216 lngelheim, Germany ("'BI") and FIBROGEN, INC. 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between BOEHRINGER INGELHEIM PHARMA GMBH & Co. KG, Birkendorfer Str.65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FIBROGEN on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No.4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 1, 2012, Amendment No. 8, effective as of July 10, 2

Amendment No. 15 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

THIS AMENDMENT No. 15 (the "Fifteenth Amendment "), effective as of October 20, 2014 (the "Fifteenth Amendment Effective Date") by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 lngelheim, Germany ("BI'') and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer lngelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011,

Amendment No. 18 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

THIS AMENDMENT No. 18 (the "Eighteenth Amendment"), effective as of February 15, 2015 (the "Eighteenth Amendment Effective Date") by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 05, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10,

Amendment No. 21 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

This AMENDMENT No. 21 (the "Twenty-first Amendment"), effective as of May 29, 2015 (the "Twenty first Amendment Effective Date") by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 lngelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA ("FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer lngelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 201 l, Amendment No. 7, effective as of January 01 , 2012, Amendment No. 8, effective as of July 10,

Amendment No. 20 to the Process Development and Clinical Supply Agreement (November 12th, 2015)

THIS AMENDMENT No. 20 (the "Twentieth Amendment"), effective as of June 01, 2015 (the "Twentieth Amendment Effective Date") by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany ("BI") and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (''FibroGen"), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany ("BI Pharma") and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1 , effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011 , Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 201 I , Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2

Ultragenyx Pharmaceutical Inc. – Amendment 1 ("This Amendment") to the Development and Clinical Supply Agreement With the Contract Number: E86a1d4c-B3f9 (March 27th, 2015)

The Parties amend their Development and Clinical Supply Agreement with the Contract Number: E86A1D4C-B3F9, effective as of 31 August 2012, ("the Agreement") as follows:

This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. Product Development and Clinical Supply Agreement (February 27th, 2015)

THIS PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (this Agreement) is made effective as of the 23rd day of October, 2014 (the Effective Date) by and between BAXTER PHARMACEUTICAL SOLUTIONS LLC, a Delaware limited liability company having a place of business at 927 South Curry Pike, Bloomington, Indiana 47403 (Baxter), and GENOCEA BIOSCIENCE, INC., a Delaware corporation having a principal place of business at Cambridge Discovery Park, 100 Acorn Park Dr., 5th Floor, Cambridge, MA, 02140 (Client).

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. DRUG CLINICAL SUPPLY AGREEMENT (January 13th, 2015)

This Drug Clinical Supply Agreement (this Agreement) is entered into as of February 9, 2014 (the Effective Date) by and between by and between INO Therapeutics LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (Ikaria), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (Pulse Technologies). Ikaria and Pulse Technologies may be individually referred to as a Party and together as the Parties.

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. DEVICE CLINICAL SUPPLY AGREEMENT (January 13th, 2015)

This Device Clinical Supply Agreement (this Agreement) is entered into as of February 9, 2014 (the Effective Date) by and between by and between INO Therapeutics LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (Ikaria), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (Pulse Technologies). Ikaria and Pulse Technologies may be individually referred to as a Party and together as the Parties.

ProQR Therapeutics B.V. – License and Clinical Supply Agreement (October 9th, 2014)

THIS LICENSE AND CLINICAL SUPPLY AGREEMENT (Agreement) is effective as of October 8, 2014 (the Effective Date), and is by and between PARI PHARMA GMBH, a German corporation having its principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (PARI) and PROQR THERAPEUTICS N.V., a company organized under the laws of the Netherlands, having its corporate seat at Leiden and its offices at Darwinweg 24, 2333 CR Leiden, the Netherlands (ProQR). PARI and ProQR are individually a Party or collectively Parties.

Amendment No. 7 to the Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 7 (the Seventh Amendment), effective as of January 01, 2012 (the Seventh Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, and Amendment No. 6, effective as of May 26, 2011 (hereinafter together the Supply Agreement). BI Pharma and FibroGen shall be referred to individually herein as a Party, and collectively as, the Parties.

Amendment No. 9 to the Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 9 (the Ninth Amendment), effective as of November 26, 2012 (the Ninth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, and Amendment No. 8 (which is under negotiation simultaneously) (hereinafter together the Supply Agreement). BI Pharma and FibroGen shall be re

Amendment No. 1 (Hereinafter Called the Amendment) to the Process Development and Clinical Supply Agreement Effective as of 29 November 2007 and Signed by the Parties on November 29 and December 03, 2007 Between FibroGen Inc. (October 1st, 2014)

The Parties entered into the Process Development and Clinical Supply Agreement, effective as of 29 November 2007 and signed by the Parties on November 29 and December 03, 2007, which has been modified by the Letter Agreements entered into on 26 June 2008 and 18 August 2008 (hereinafter together called the Agreement).

Amendment No. 5 to the Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 5 (the Fifth Amendment) is effective as of April 15, 2011 (the Fifth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen) amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, the Amendment No. 1, effective as of May 28, 2009, the Amendment No. 3, effective as of November 5, 2010, and the Amendment No. 4, effective as of January 24, 2011 (hereinafter together the Supply Agreement). BI Pharma and FibroGen shall be referred to individually herein as a Party, and collectively as, the Parties.

Amendment No. 10 to the Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 10 (the Tenth Amendment), effective as of June 21, 2013 (the Tenth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012 and Amendment No. 9, effective as of November 26, 2012 (hereinafter together the Supply Agreement).

Amendment No. 4 to Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 4 (the Fourth Amendment) is effective as of January 24, 2011 (the Fourth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG (BI Pharma) and FibroGen, Inc. (FibroGen) amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of on June 26, 2008 and August 18, 2008, the First Amendment on May 14, 2009 and the Third Amendment on November 5, 2010 (the Supply Agreement). BI Pharma and FibroGen shall be referred to individually herein as a Party, and collectively as, the Parties.

Amendment No. 14 to the Process Development and Clinical Supply Agreement Between Fibrogen, Inc. And Boehringer Ingelheim Pharma Gmbh & Co. Kg (October 1st, 2014)

THIS AMENDMENT NO. 14 (the Fourteenth Amendment), effective as of February 5, 2014 (the Thirteenth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of

Amendment No. 6 to the Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 6 (the Sixth Amendment), effective as of May 26, 2011 (the Sixth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011 (the Fourth Amendment), and Amendment No. 5, effective as of April 15, 2011 (hereinafter together the Supply Agreement). BI Pharma and FibroGen shall be referred to individually herein as a Party, and collectively as, the Parties.

Amendment No. 12 to the Process Development and Clinical Supply Agreement (October 1st, 2014)

THIS AMENDMENT NO. 12 (the Twelfth Amendment), effective as of August 01, 2013 (the Twelfth Amendment Effective Date) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany (BI Pharma) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (FibroGen), amends the Process Development and Clinical Supply Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of June 2